Skip to content
MadInfo
Home/Health/SESARAM boosts anti-hemorrhagic drug stock with in...
Health1 min read

SESARAM boosts anti-hemorrhagic drug stock with investment over 700 thousand euros

The Regional Secretariat for Health and Civil Protection has published Ordinance no. 179/2026, which proceeds with the redistribution and amendment of budgetary burdens for the acquisition of anti-hemorrhagic drugs, specifically the medication Eftrenonacog Alfa, intended for the Health Service of the Autonomous Region of Madeira, EPERAM (SESARAM).

The global base price for the acquisition is 706,212.15 €, plus VAT at a rate of 6%. The financial burden has been fully allocated to the 2026 fiscal year, ensuring the continuity of specialized healthcare required for users of the regional service.

Related articles